TABLE 1.
Baseline characteristics of patients (n = 23)
| Characteristics | Number of patients [cases (%)] |
|---|---|
| Age, year [median (range)] | 63 (44–75) |
| <60 | 10 (43.5) |
| ≥60 | 13 (56.5) |
| Gender | |
| Male | 18 (78.3) |
| Female | 5 (21.7) |
| ECOG PS score | |
| 0 | 15 (65.2) |
| 1 | 8 (34.8) |
| Histologic grade | |
| G1 | 1 (4.3) |
| G2 | 9 (39.1) |
| G3 | 5 (21.7) |
| Unknown | 8 (34.8) |
| Number of organs with metastasis | |
| 1 | 11 (47.8) |
| ≥2 | 12 (52.2) |
| Site of metastases | |
| Lymph node | 20 (87.0) |
| Lung | 8 (34.8) |
| Liver | 3 (13.0) |
| Bone | 3 (13.0) |
| Others | 4 (17.4) |
| PD‐L1 expression | |
| <1% | 2 (8.7) |
| ≥1% | 16 (69.6) |
| <5% | 5 (21.7) |
| ≥5% | 13 (56.5) |
| <10% | 6 (26.1) |
| ≥10% | 12 (52.2) |
| <25% | 14 (60.9) |
| ≥25% | 4 (17.4) |
| Unevaluable | 5 (21.7) |
| Previous treatment | |
| Surgery | 9 (39.1) |
| Radiotherapy | 4 (17.4) |
| Adjuvant or neoadjuvant chemotherapy | 5 (21.7) |
| Extent of disease | |
| Unresectable locally advanced | 1 (4.3) |
| Metastatic disease | 22 (95.7) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status.